Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00520936 · OUTCOME

Pharmacogenomics - Measure the Response of Genes Related to Toxicity

A Study of Pemetrexed in Children With Recurrent Cancer · Source last updated 2011-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Correlation coefficient
Interval / dispersion
Not reported
Time frame
baseline

What was measured

The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.

Analysis population: The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here.

Groups in this outcome

Osteosarcoma

Pemetrexed 1910 milligrams per meters squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old)

Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Rhabdomyosarcoma

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Neuroblastoma (Measureable Disease)

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Ependymoma

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Non-Brainstem High-Grade Glioma

Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osteosarcoma0
Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors0
Rhabdomyosarcoma0
Neuroblastoma (Measureable Disease)0
Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)0
Ependymoma0
Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor0
Non-Brainstem High-Grade Glioma0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      0
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      0
    7. group Id
      OG006
      value
      0
    8. group Id
      OG007
      value
      0
    units
    Participants
description
The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.
groups
  1. description
    Pemetrexed 1910 milligrams per meters squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old)
    id
    OG000
    title
    Osteosarcoma
  2. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG001
    title
    Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors
  3. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG002
    title
    Rhabdomyosarcoma
  4. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG003
    title
    Neuroblastoma (Measureable Disease)
  5. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG004
    title
    Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)
  6. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG005
    title
    Ependymoma
  7. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG006
    title
    Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor
  8. description
    Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
    id
    OG007
    title
    Non-Brainstem High-Grade Glioma
param Type
NUMBER
population Description
The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here.
reporting Status
POSTED
time Frame
baseline
title
Pharmacogenomics - Measure the Response of Genes Related to Toxicity
type
SECONDARY
unit Of Measure
Correlation coefficient

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice